Skip to main content

Advertisement

SpringerLink
Log in

Biodistributions of 177Lu- and 111In-Labeled 7E11 Antibodies to Prostate-Specific Membrane Antigen in Xenograft Model of Prostate Cancer and Potential Use of 111In-7E11 as a Pre-therapeutic Agent for 177Lu-7E11 Radioimmunotherapy

  • Research Article
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Introduction

Prostate-specific membrane antigen is a transmembrane glycoprotein highly expressed in many prostate cancers and can be targeted with radiolabeled antibodies for diagnosis and treatment of this disease. To serve as a radioimmunotherapeutic agent, a kinetically inert conjugate is desired to maximize tumor uptake and tumor radiation dose with minimal nonspecific exposure to bone marrow and other major organs.

Materials and Methods

In this study, we assessed the pharmacokinetics and biodistribution of the 7E11 monoclonal antibody (MAb) radiolabeled with the lutetium-177 (177Lu)–tetraazacyclododecanetetraacetic acid conjugate system (177Lu-7E11) versus those of the 7E11 MAb radiolabeled with the indium-111 (111In)/glycyl-tyrosyl-(N,-diethylenetriaminepentaacetic acid)/lysine hydrochloride conjugate system (111In-7E11, also known as ProstaScint®) to determine the feasibility of using 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy. Pharmacokinetic and biodistribution studies of 177Lu-7E11 in lymph node cancer of the prostate (LNCaP) xenograft mice were performed at 2, 8, 12, 24, 72, and 168 h after radiopharmaceutical administration. For 111In-7E11, pharmacokinetic and biodistribution studies were performed at 8, 24, and 72 h. Parallel studies of 177Lu-7E11 in non-tumor-bearing mice at 8, 24, and 72 h post-injection served as controls. Gamma scintigraphy was performed, followed by autoradiography and tissue counting, to demonstrate and quantify the distributions of radioconjugated MAb in the tumor and normal tissues.

Results and Discussion

Both 177Lu- and 111In-7E11 conjugates demonstrated an early blood pool phase in which uptake was dominated by the blood, lung, spleen and liver, followed by uptake and retention of the radiolabeled antibody in the tumor which was most prominent at 24 h. Total accumulation of radioconjugated MAb in tumor at 24 h was greater in the case of 177Lu-7E11 in comparison to that of 111In-7E11. Continued accumulation in tumor was observed for the entire time course studied for both 177Lu-7E11 and 111In-7E11. The liver was the only major organ demonstrating a significant difference in accumulation between the two conjugates. In conclusion, pharmacokinetic and biodistribution studies of 177Lu-7E11 in LNCaP xenograft mouse models support its potential application as a radioimmunotherapeutic agent targeting prostate cancer, and the distribution and tumor uptake of 111In-7E11 appear to be similar to those of 177Lu-7E11, supporting its use as a pre-therapeutic tool to assess the potential accumulation of 177Lu-7E11 radioimmunotherapeutic at sites of prostate cancer. However, the different accumulation patterns of the 111In and 177Lu immunoconjugates in liver will likely prevent the use of 111In-7E11 as a true dosimetry tool for 177Lu-7E11 radioimmunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Swanson GP, Thompson IM, Basler J (2006) Current status of lymph node-positive prostate cancer: incidence and predictors of outcome. Cancer 107:439–450

    Article  PubMed  Google Scholar 

  2. Swanson GP, Thompson IM, Basler J (2006) Treatment options in lymph node-positive prostate cancer. Cancer 106:2531–2539

    Article  PubMed  Google Scholar 

  3. Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098–1109

    Article  PubMed  CAS  Google Scholar 

  4. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23:4591–4601

    Article  PubMed  CAS  Google Scholar 

  5. Russell PJ, Hewish D, Carter T et al (2004) Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies. Cancer Immunol Immunother 53:411–421

    Article  PubMed  CAS  Google Scholar 

  6. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH (2000) In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 60:5237–5243

    PubMed  CAS  Google Scholar 

  7. Wright GL Jr, Grob BM, Haley C et al (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326–334

    Article  PubMed  Google Scholar 

  8. Fair WR, Israeli RS, Heston WD (1997) Prostate-specific membrane antigen. Prostate 32:140–148

    Article  PubMed  CAS  Google Scholar 

  9. Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH (2006) Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 26:5310–5324

    Article  PubMed  CAS  Google Scholar 

  10. Troyer JK, Beckett ML, Wright GL Jr (1995) Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62:552–558

    Article  PubMed  CAS  Google Scholar 

  11. Troyer JK, Beckett ML, Wright GL Jr (1997) Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30:232–242

    Article  PubMed  CAS  Google Scholar 

  12. Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7:927–935

    PubMed  CAS  Google Scholar 

  13. Barren RJ 3rd, Holmes EH, Boynton AL, Misrock SL, Murphy GP (1997) Monoclonal antibody 7E11.C5 staining of viable LNCaP cells. Prostate 30:65–68

    Article  PubMed  Google Scholar 

  14. Elgamal AA, Troychak MJ, Murphy GP (1998) ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate 37:261–269

    Article  PubMed  CAS  Google Scholar 

  15. Feneley MR, Jan H, Granowska M et al (2000) Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer. Prostate Cancer Prostatic Dis 3:47–52

    Article  PubMed  Google Scholar 

  16. Tedesco J, Goeckeler W, Becker M, Frank K, Gulyas G, Young S (2005) Development of optimal Lu-177 labeled monoclonal antibody (7E11) construct (CYT-500) for radioimmunotherapy of hormone refractory prostate cancer. J Clin Oncol 23(16S):4765

    Google Scholar 

  17. Tedesco J, Wolodzco J, Goeckeler W, Becker M, Hasegawa B, Franc B (2006) Development and characterization of a novel 177Lu-MeO-DOTA-7E11 antibody construct (CYT-500) for the treatment and imaging of prostate adenocarcinoma. AACR Annual Meeting

  18. Nargund V, Al Hashmi D, Kumar P et al (2005) Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging. BJU Int 95:1232–1236

    Article  PubMed  Google Scholar 

  19. Christiansen JJ, Rajasekaran SA, Inge L, Cheng L, Anilkumar G, Bander NH, Rajasekaran AK (2005) N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy. Mol Cancer Ther 4:704–714

    Article  PubMed  CAS  Google Scholar 

  20. Bander NH, Trabulsi EJ, Kostakoglu L et al (2003) Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 170:1717–1721

    Article  PubMed  CAS  Google Scholar 

  21. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH (2004) Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22:2522–2531

    Article  PubMed  CAS  Google Scholar 

  22. O'Donoghue JA, Bardies M, Wheldon TE (1995) Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36:1902–1909

    PubMed  Google Scholar 

  23. Seo Y, Wong KH, Sun M, Franc BL, Hawkins RA, Hasegawa BH (2005) Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system. J Nucl Med 46:868–877

    PubMed  Google Scholar 

Download references

Acknowledgments

Research Funding and 7E11 antibody were provided by the Cytogen Corporation for this project. LNCaP cells transfected with luciferase were kindly supplied by the Contag laboratory at Stanford University. The authors also acknowledge support from NIH Grant 5R01EB000348 and 5K25CA114254. This paper is dedicated to the memory of John Tedesco and Bruce Hasegawa who sadly passed away before seeing this paper come out.

Author information

Authors and Affiliations

  1. Center for Molecular and Functional Imaging, Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94143, USA

    Mei-Hsiu Pan, Dong-Wei Gao, Jinjin Feng, Jiang He, Youngho Seo, Bruce H. Hasegawa & Benjamin L. Franc

  2. Cytogen Corporation, Princeton, NJ, 08540, USA

    John Tedesco & John G. Wolodzko

Authors
  1. Mei-Hsiu Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dong-Wei Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jinjin Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiang He
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Youngho Seo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John Tedesco
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. John G. Wolodzko
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bruce H. Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Benjamin L. Franc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Youngho Seo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pan, MH., Gao, DW., Feng, J. et al. Biodistributions of 177Lu- and 111In-Labeled 7E11 Antibodies to Prostate-Specific Membrane Antigen in Xenograft Model of Prostate Cancer and Potential Use of 111In-7E11 as a Pre-therapeutic Agent for 177Lu-7E11 Radioimmunotherapy. Mol Imaging Biol 11, 159–166 (2009). https://doi.org/10.1007/s11307-008-0185-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-008-0185-9

Key words

Search

Navigation